

The Decipher Bladder Test Helps You and Your Doctor Make a Personalized Decision in Your Bladder Cancer Care

If you answered **yes** to the questions, then Decipher Bladder test may be for you.

Contact your doctor to find out how Decipher might play a role in your treatment planning or contact the GenomeDx Customer Support Team:

- 1.888.792.1601 (toll free)
- customersupport@genomedx.com
- DecipherTest.com

Based on each patient's individual tumor genomics, Decipher Bladder:

- Identifies which patients with muscle invasive bladder cancer who may respond to neoadjuvant chemotherapy prior to radical cystectomy

Access for All Patients

- All insurances accepted
- Proven and comprehensive financial assistance for patients

To learn more about Decipher, contact the GenomeDx Customer Support Team:

1.888.792.1601 (toll free)
customersupport@genomedx.com
DecipherTest.com



Answer the following questions to determine if Decipher Bladder is right for you:

YES NO

Have you been diagnosed with Muscle Invasive Bladder Cancer? YES NO


Have you had a transurethral resection of bladder tumor (TURBT) procedure? YES NO

Did your doctor indicate you may be a candidate for bladder removal surgery? YES NO

fold in brochure flap for your next step. . .

Decipher Bladder predicts which patients with Muscle Invasive Bladder Cancer:

- May benefit from neoadjuvant chemotherapy prior to bladder removal surgery (radical cystectomy)
- May be considered for immediate bladder removal surgery (radical cystectomy)



How Decipher Bladder Works:

- Advanced genomic testing is performed on a specimen of tissue removed by your surgeon during your transurethral resection of bladder tumor (TURBT) procedure. You do not have to undergo any further procedures to get Decipher Bladder.
- Assigns your tumor into one of four molecular subtypes
- Subtypes are used by your doctor to determine optimal treatment for your tumor

Reference:

Seiler, R., et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival outcome to neoadjuvant chemotherapy: results from a multi-institutional validation study. Presented at the Annual Meeting of the Society of Urologic Oncology, 2016